CIC
CRVS icon

Cornercap Investment Counsel’s Corvus Pharmaceuticals CRVS Stock Holding History

Cornercap Investment Counsel’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-97,248
Closed -$223K – 591
2023
Q2 		$223K Buy
+97,248
New +$202K 0.04% 496

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TL
TowerView LLC New York $152M AUM 20.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cornercap Investment Counsel's CRVS Position: Q3 2023 in Review

Cornercap Investment Counsel sold out of Corvus Pharmaceuticals (CRVS) in Q3 2023, closing a stake of 97,248 shares — an estimated $223K sold.

Cornercap Investment Counsel first reported a position in CRVS in Q2 2023 and held it in 1 quarter. The position peaked at $223K in Q2 2023. 52 funds tracked by Wall St. Rank hold CRVS as of Q3 2023.

  • Cornercap Investment Counsel reported no remaining Corvus Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Cornercap Investment Counsel sold 97,248 Corvus Pharmaceuticals shares in Q3 2023, an estimated $223K.
  • Cornercap Investment Counsel first reported a position in Corvus Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Cornercap Investment Counsel's Corvus Pharmaceuticals position peaked at $223K in Q2 2023.
  • 52 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2023.

Based on Cornercap Investment Counsel's 13F filing for Q3 2023, filed 13 Nov 2023.